Drug intelligence / Profile preview

META-1i-AID

Development stage: Preclinical
Lead developer: META Pharmaceuticals
Modality: Small Molecules

Overview

META-1i-AID is a small molecule drug candidate currently in preclinical development by META Pharmaceuticals Inc. It is being investigated for its potential to treat immune system diseases, specifically autoimmune diseases. The drug's development leverages an AI-driven drug discovery platform, focusing on the emerging field of immunometabolism, which involves modulating the metabolic pathways of immune cells to achieve therapeutic effects. META Pharmaceuticals Inc. aims for this drug to be a first-in-class original product for self-responsive diseases.

Beyond the preview

Go deeper on META-1i-AID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on META-1i-AID.

Explore the full profile